Board of Directors

• Richard H. Aldrich
• Ronald W. Barrett
• Douglas G. Cole
• Jens W. Eckstein
• Stephen J. Hoffman
• Peter Barton Hutt
• Wilfred E. Jaeger
• Roger D. Tung
  

Richard H. Aldrich
Chairman of the Board
Co-Founder and Partner, Longwood Founders Fund

Mr. Aldrich is a co-founder of Concert Pharmaceuticals and has served as our Chairman of the Board since May 2006. Mr. Aldrich co-founded Longwood Founders Fund in 2010, a fund that starts and invests in biotechnology companies, and currently serves as a Partner in the firm. Prior to Longwood, he was General Partner of RA Capital, a biotech investment fund he founded in 2001. Mr. Aldrich was a co-founding employee of Vertex Pharmaceuticals where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen Inc. In addition to Concert, Mr. Aldrich has co-founded and helped build several successful biotech companies including Sirtris Pharmaceuticals and Alnara Pharmaceuticals. Mr. Aldrich received his undergraduate degree from Boston College, and an MBA from the Amos Tuck School at Dartmouth College.

[ back to top ]

Ronald W. Barrett, Ph.D.
Chief Executive Officer, XenoPort, Inc.

Dr. Barrett has served as a member of our Board of Directors since December 2007.  He is a founder of XenoPort, Inc. and since 2001 has served as its Chief Executive Officer.   From 1999 to 2001 he served as Chief Scientific Officer of XenoPort.  From 1989 to 1999 he held various positions at Affymax Research Institute (acquired by Glaxo Wellcome in 1995), the most recent of which was Senior Vice President of Research.  Prior to Affymax Research Institute, Dr. Barrett was a molecular pharmacologist in the Neuroscience Group at Abbott Laboratories from 1986 to 1989. He is also a member of the Board of Directors of XenoPort.  Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in pharmacology from Rutgers University.

[ back to top ]

Douglas G. Cole, M.D.
General Partner, Flagship Ventures

Dr. Cole has been a member of our Board of Directors since November 2006.  He has served as General Partner of Flagship Ventures since 2001.  From 1997 to 2001 he was a Program Executive at Vertex Pharmaceuticals Inc. and from 1996 to 1997 he was Medical Director at Cytotherapeutics.  He is also a member of the Board of Directors of Agios Pharmaceuticals, Inc.; AVEO Pharmaceuticals, Inc.; CGI Pharmaceuticals, Inc.; Ensemble Discovery Corporation; Quanterix Corporation; and Tetraphase Pharmaceuticals, Inc.  Dr. Cole holds an A.B., magna cum laude, in English from Dartmouth College, where he was a Senior Fellow and an M.D. from the University of Pennsylvania School of Medicine.

[ back to top ]

Jens W. Eckstein, Ph.D.
General Partner, TVM Capital

Dr. Eckstein has been a member of our Board of Directors since December 2007. Dr. Eckstein joined TVM Capital in 2004, and currently serves as General Partner in the firm’s life sciences practice where he focuses on earlier-stage investments. Prior to joining TVM Capital, Dr. Eckstein was founder and president of Akikoa Pharmaceuticals, Inc. Before that Dr. Eckstein was Director of Lead Discovery and Research IT at Enanta Pharmaceuticals, Inc. from 1998 to 2003. Before joining Enanta, he managed research groups in biochemistry, structural biology, and computational chemistry at Mitotix, Inc. (now GPC-Biotech) from 1993 to 1998. He is a member of the Board of Directors of Ascent Therapeutics, Inc. and Magen BioSciences, Inc. Dr. Eckstein earned his doctorate, summa cum laude, in biological chemistry at the University of Konstanz and Harvard University. He was a postdoctoral fellow at the University of California in San Francisco (UCSF).

[ back to top ]

Stephen J. Hoffman, M.D., Ph.D.
Managing Director, Skyline Ventures

Dr. Hoffman has been a member of our Board of Directors since May 2006.  Dr. Hoffman currently serves as Managing Director of Skyline Ventures, a venture capital firm.  Prior to joining Skyline Ventures in May 2007, Dr. Hoffman was a General Partner of TVM Capital.  From 1994 to 2001 he served as President and Chief Executive Officer of Allos Therapeutics, Inc. and as Executive Chairman from 2001 to 2002.  Dr. Hoffman is Chairman of the Board of Allos Therapeutics.  He received a Ph.D. in chemistry from Northwestern University and an M.D. from the University of Colorado.  Dr. Hoffman completed a fellowship in clinical oncology and a residency and immunodermatology fellowship, all at the University of Colorado. 

[ back to top ]

Peter Barton Hutt
Senior Counsel, Covington & Burling LLP

Mr. Hutt has been a member of our Board of Directors since December 2006.  He currently serves as senior counsel at Covington & Burling LLP, a law firm specializing in food and drug law. He began his law practice with the firm in 1960 and, except for his four years in the government, has continued at the firm ever since. From 1971 to 1975 he was Chief Counsel for the Food and Drug Administration.  Mr. Hutt is a member of the Board of Directors of eight venture capital startup companies, and on the Advisory Board of six venture capital firms.  Mr. Hutt received his undergraduate degree from Yale University, and law degrees from Harvard University and New York University.

[ back to top ]

Wilfred E. Jaeger, M.D.
Partner, Three Arch Partners

Dr. Jaeger has been a member of our Board of Directors since May 2006.  Dr. Jaeger co-founded Three Arch Partners, a venture capital firm, in 1993 and has served as a Partner since that time.  Prior to co-founding Three Arch Partners, Dr. Jaeger was a general partner at Schroder Ventures.  He is also a member of the Board of Directors of North American Scientific, Inc. and Threshold Pharmaceuticals, Inc., as well as numerous private companies.   Dr. Jaeger received a B.S. in Biology from the University of British Columbia, his M.D. from the University of British Columbia School of Medicine and an M.B.A. from Stanford University.

[ back to top ]

Roger D. Tung, Ph.D.
President and CEO, Concert Pharmaceuticals, Inc.

Dr. Tung has been a member of our Board of Directors since May 2006.  He is a co-founder of Concert Pharmaceuticals, Inc. and since April 2006 has served as its President and Chief Executive Officer.  Dr. Tung wasa founding scientist of Vertex Pharmaceuticals Inc. and from 1989 to 2005 he held various positions, the most recent of which was Vice President of Drug Discovery.  He also held positions at Merck, Sharp & Dohme Research Laboratories and The Squibb Institute for Medicinal Chemistry before joining Vertex.  Dr. Tung received his Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison.

[ back to top ]